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The residues contributing to the thioester bonds in bovine q-macroglobulin were differentially labelled by 
modification of the Glu moiety with [Y]methylamine and of the Cys moiety with iodo[3H]acetate. The 
labelled region was identified and analyzed in a tryptic peptide. Two amino acid replacements between hu- 
man and bovine q-macroglobulin were found at positions + 3 (Val/Ala) and +4 (Leu/Arg) from the Glu 
moiety of the thioester. Thus, marked differences exist between the human and bovine proteins in side chain 
size and charge close to the thioester bonds. These differences may explain the greater conformational stabil- 
ity of bovine a:-macroglobulin, compared with that of the human inhibitor, after cleavage of the thioester 
bonds. 
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1. INTRODUCTION 
a2-Macroglobulin is a high-molecular-mass 
tetrameric plasma protease inhibitor with wide 
specificity [1,2]. Its inactivation of proteases is in- 
itiated by restricted proteolysis of a specific ‘bait’ 
region of the inhibitor polypeptide chain. This trig- 
gering event leads to cleavage of a thioester bond, 
present in each subunit of az-macroglobulin, and 
to a conformational change that is involved in 
binding of the protease [1,3-l 11. The inactivated 
enzyme is bound in a manner that abolishes its ac- 
tivity only against macromolecular substrates. The 
protease may thus be physically entrapped by the 
inhibitor [I], Maximally two enzyme molecules can 
be bound per cYz-macroglobulin tetramer 
[4-6,12,13]. 
Nucleophilic cleavage of the thioester bonds of 
human a2-macroglobulin by amines leads to a con- 
Sequence homology Conformational change 
formational change similar to that induced by pro- 
teases and is associated with inactivation of the in- 
hibitor [4,6,8-l 11. In contrast, no analogous con- 
formational change occurs on cleavage of the 
thioester bonds of bovine az-macroglobulin, and 
this inhibitor also retains activity after the thioester 
bond cleavage [14,15]. Recent studies have shown 
that cyanylation of the liberated sulfhydryl group 
of human cyt-macroglobulin concomitant with the 
cleavage of the thioester bond largely prevents the 
change of conformation and loss of activity of this 
protein [16,17]. Thus, the extent of the conforma- 
tional change can be affected by minor structural 
changes in the thioester bond region. Consequent- 
ly, the greater conformational stability of bovine 
cuz-macroglobulin than of the human inhibitor, in 
the absence of an intact thioester bond, could arise 
from residue replacements close to this bond. To 
test this possibility, we have determined the amino 
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acid sequence of the thioester bond region of 
bovine az-macroglobulin and compared it with the 
known structure of this region of the human in- 
hibitor [ 181. 
2. MATERIALS AND METHODS 
Bovine crz-macroglobulin was purified and its 
concentration was determined as described [ 151. 
The glutamic acid moiety of the thioester bond was 
labelled by reacting the protein (4 mg/ml) with 10 
mM [14C]methylamine (spec. act. 53 GBq/mol; 
Amersham, England) for 16 h (i.e. about 5 x tl/2 
for the thioester bond cleavage [IS]) at 25°C in 0.1 
M Hepes /NaOH, 0.1 M NaCl, pH 8.2. Unlabelled 
methylamine was then added to a concentration of 
100 mM, and the reaction was continued for 1 h. 
The cysteine moiety of the thioester bond was 
labelled in another batch of az-macroglobulin by 
treatment with 100 mM unlabelled methylamine in 
the presence of 1 mM iodo[2-3H]acetate (spec. act. 
2150 GBq/mol; Amersham) for 3 h (i.e. about 10 
x f1/2) at 25°C in the Hepes buffer. In both cases, 
excess reagents were removed by exclusion 
chromatography on Sephadex G-50 (Pharmacia, 
Sweden). 
A mixture of the separately labelled batches of 
cuz-macroglobulin (total cont. 5 mg/ml) was re- 
duced for 4 h with 10 mM dithiothreitol in 0.4 M 
Tris/HCl, 6 M guanidine/HCl, 10 mM EDTA, pH 
8.2, and then carboxymethylated by the addition 
of unlabelled iodoacetate to a concentration of 25 
mM. After 30 min, mercaptoethanol was added to 
50 mM, and the material was dialyzed extensively 
against 1 mM HCl. Trypsin (treated with p-tosyl- 
L-phenylalanine chloromethyl ketone) was added 
in an amount corresponding to a trypsin/protein 
ratio of l/100 by weight, pH was raised to 8.0, and 
the solution was made 0.1 M in ammonium bicar- 
bonate. Digestion was allowed to proceed for 4 h 
at 37’C with continuous stirring. 
The tryptic peptides obtained were immediately 
fractionated by chromatography (25 ml/h) on a 
column (2.5 x 90 cm) of Sephadex G-75 Superfine 
(Pharmacia) in 0.1 M ammonium bicarbonate. 
Further separation was achieved by gel permeation 
HPLC at 2.4 ml/h in 0.1 M ammonium acetate on 
an UltroPac TSK G-2000SW column (0.75 x 
60 cm; LKB, Sweden). Final isolation of the la- 
belled peptide was carried out by two reverse-phase 
88 
HPLC steps on apBondapak Cl8 column (0.39 x 
30 cm; Waters). In the first step, the column was 
eluted at 1 ml/min with a linear gradient of 
acetonitrile (O-70% in 70 ml) in 0.1% 
trifluoroacetic acid. The second step involved 
rechromatography with a more shallow gradient 
(20-35% in 30 ml, starting after an isocratic elu- 
tion of about 10 ml at 20%). The pure, labelled 
peptide was analyzed for total composition after 
acid hydrolysis and subsequent phenylthiocar- 
bamyl conversion [19], and for amino acid se- 
quence by degradation in a liquid-phase sequencer 
(Beckman 89OD), supplemented by HPLC 
(Hewlett Packard 1090) identification of 
thiohydantoin derivatives [20]. 
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Fig.1. Final purification by reverse-phase HPLC of the 
labelled peptide derived from the segment of bovine 
,zz-macroglobulin originally containing the thioester 
bond. (A) Chromatography of the radioactive fraction 
from the preceding exclusion chromatography step. (B) 
Re-purification of the radioactive material from A, giv- 
ing final separation of two peptides. The positions of the 
labelled peptide are indicated by arrows. The column 
was developed with a gradient of acetonitrile @‘oB) in 
0.1% trifluoroacetic acid. 
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3. RESULTS 
The glutamic acid and cysteine moieties forming 
the thioester bond of bovine cYz-macroglobulin 
were labelled in separate batches of the protein 
with [14C]methylamine and iodo[Z3H]acetic acid. 
Incorporations of 0.85 and 1 .l mol of the two 
labelled reagents per mol of protein monomer were 
obtained, consistent with one thioester bond per 
subunit [14,15]. The two separately labelled pro- 
tein preparations were mixed to given a 3H: 14C 
dpm ratio of 9.7. 
Table 1 
Analytical data for the labelled peptide obtained from 
the second reverse-phase HPLC step. (A) Total com- 
position, derived from analysis after phenylthiocar- 
bamyl conversion [ 191. A low recovery of methionine, as 
in this case, is sometimes observed. Values from the se- 
quence analysis are given within parentheses. (B) Results 
of liquid-phase sequencer degradations. Values below 
the residues indicate nmol recovered. The two bottom 
lines show radioactivity in all extracts (expressed in % of 
maximal recovery, which is about 12000 cpm 3H in ex- 
tract 12 and 3000 cpm r4C in extract 15), establishing the 
positions of the 3H and 14C labels. The modified 
glutamine derivative in cycle 15 behaved almost in- 
distinguishably from the phenylthiohydantoin derivative 
of glutamine in the HPLC analysis 
A 
Residue 
Cys(Cm) 
Asx 
Thr 
Ser 
Glx 
Pro 
Gly 
Ala 
Met 
Leu 
Tyr 
Arg 
mol/mol 
0.7 (1) 
2.8 (3) 
1.1 (1) 
0.4 (-) 
3.7 (4) 
1.0 (1) 
2.1 (2) 
1.3 (1) 
1.4 (2) 
1.6 (2) 
0.8 (1) 
1.0 (1) 
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The double-labelled protein (50 nmol tetramer) 
was reduced, carboxymethylated, dialyzed, 
digested with trypsin, and subjected to exclusion 
chromatography on Sephadex G-75 (see section 2). 
One symmetric peak of radioactivity, eluting at 
Kd - 0.70, was obtained, accounting for - 60% of 
the original radioactivity measured before reduc- 
tion. This fraction was further separated by gel 
permeation HPLC on TSK G2OOOSW, producing 
only one, symmetric peak of radioactivity, eluting 
at Kd-0.72 and accounting for -4OVo of the 
original radioactivity. The material in this peak 
was further purified by reverse-phase HPLC 
(fig.lA). One radioactive peak was recovered in a 
yield of - 13% of the radioactivity in the original 
starting material. The 3H: t4C dpm ratio for this 
peptide was 9.7, identical to that of the original 
material, indicating no preferential loss of either 
labelled group. An attempt at sequence analysis at 
this stage showed that the material corresponding 
to the radioactivity peak contained two peptides in 
an approximate ratio of 2: 1. Although two 
residues were obtained in each cycle, both struc- 
tures could be identified because of the difference 
in recovery between the two peptides. The struc- 
tures deduced were homologous with two different 
regions in the known primary structure of the 
human form of the protein [18]. Thus, the minor 
peptide was tentatively identified as 
Ser-49-Lys-58, containing no radioactivity, and 
the major peptide as Asn-938-Arg-956, containing 
all the radioactivity. 
To prove these identifications, the peptide mix- 
ture was resolved by a second step of HPLC 
(fig.lB), with a more shallow gradient of 
acetonitrile than in the initial step (fig.lA). As ex- 
pected, the radioactivity was recovered in the ma- 
jor peptide, and the structure tentatively assigned 
to this peptide was completely verified (table 1). 
These results establish the amino acid sequence 
around the thioester bond in bovine 
aa-macroglobulin. 
_ 
Asn- Thr- Gln- Asn- Leu- Leu- Gln- Met- Pro- Tyr- Gly- Cys- Gly- Glu- Glx- Asn-Met- Ala- Arg 
2.3 2.2 1.9 2.1 3.9 3.9 1.4 3.2 1.8 2.7 2.3 1.6 1.9 1.7 1.3 0.9 1.3 1.9 0.2 
‘H: 111122122 2 100 57 17 5 3 3 2 2 
14c: 4453455443 86 6 100 60 33 14 13 
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Fig.2. Comparison of the structures around the thioester bond in the subunits of human (top) and bovine (bottom) 
cY2-macroglobulin. The bovine protein structure is from the present analysis (table l), the human one and the numbering 
system (above the top line) are from [18]. The two established amino acid exchanges are boxed, as well as the probable 
difference at position 937, where an Arg or Lys (indicated by R/K) in the bovine inhibitor is indirectly deduced from 
the major tryptic cleavage that has occurred after this site. The position of the thioester bond is indicated in the top 
structure, the differential labelling used to detect the reactive residues in the present work is indicated in the bottom 
structure. 
c3 -Ser Gly-Cys-Gly-Glu-Glx-Asn-Met-Ile-Gly- 
L-,-t;, 
C4 --Arg-Gly-Cys-Gly-Glu-Glx-Thr-Het-Ile-Tyr- 
I I 
L--S -c=o 
Fig.3. Comparison of the structures around the thioester 
bond in the human complement factors C3 (top) and C4 
(bottom). The two structures are from [21,22]. 
4. DISCUSSION 
A comparison of the structures around the 
thioester bonds in human and bovine 
az-macroglobulin (fig.2) shows two amino acid ex- 
changes, the sequences of the remainder of the 
segments being identical. Thus, Val-955 and 
Leu-956 in the human protein have been replaced 
by Ala and Arg, respectively, in the bovine form. 
Both these exchanges are compatible with one-base 
mutations. The two replacements, together with 
those in the minor peptide (not shown), and that 
deduced from the presence of a tryptic cleavage 
site before the labelled major peptide (fig.2), ac- 
count for six residue differences in 31 positions. 
Consequently, the human and bovine cuz-macro- 
globulin structures appear to have a homology 
with about 80070 positional identities, a degree of 
identity similar to that between other proteins 
from the two species. 
The sequence around the thioester bond is highly 
conserved in the human thioester-containing pro- 
teins cY2-macroglobulin and the complement fac- 
tors C3 and C4 ([18,21,22]; figs 2 and 3). The 
structure of this region therefore must be of para- 
mount importance for the functional properties of 
the thioester bond. The three human proteins, 
which all undergo a major conformational change 
and are inactivated on thioester cleavage by amines 
[4,9-l 1,23,24], all have a large hydrophobic amino 
acid in position + 3 from the Glu moiety of the 
thioester and a neutral amino acid in position + 4. 
In bovine cr2-macroglobulin, which does not 
undergo a corresponding conformational change 
and which remains active on amine-treatment 
[14,15], the two amino acid replacements at these 
positions markedly alter the properties of the seg- 
ment of the chain just C-terminal of the thioester 
bond. The Arg/Leu exchange thus introduces an 
extra positive charge in this region of the bovine in- 
hibitor, and the adjacent Ala/Val exchange leads 
to a difference in the size of the side chain. 
Previous work has shown that relatively subtle 
structural changes in the thioester bond region are 
sufficient to stabilize considerably the conforma- 
tion of human a2-macroglobulin after thioester 
cleavage [16,17]. It is therefore likely that the dif- 
ferent side chain properties close to the thioester 
bond confer additional conformational stability to 
bovine az-macroglobulin, such that this protein re- 
mains in its near-native state also in the absence of 
the stabilizing thioester bonds. 
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